Article
Oncology
Subaru Sawayanagi, Hideomi Yamashita, Yuki Nozawa, Ryosuke Takenaka, Yosuke Miki, Kosuke Morishima, Hiroyuki Ueno, Takeshi Ohta, Atsuto Katano
Summary: This study aimed to identify prognostic factors and establish predictive models for survival outcomes in non-metastatic NSCLC patients treated with SBRT. The study found one radiomic factor and one predictive model that showed significant impact on overall survival and accurately estimated survival time.
Article
Oncology
Saber A. Amin, Morshed Alam, Michael J. Baine, Jane L. Meza, Nathan R. Bennion, Chi Zhang, Ibur Rahman, Chi Lin
Summary: The study investigated the impact of SBRT on the overall survival of early-stage NSCLC patients, showing that SBRT was associated with improved overall survival. The magnitude of the impact of SBRT on overall survival was found to increase in patients with advanced age, higher T stages, higher comorbidity scores, and more recent treatment eras.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Nasser K. Altorki, Timothy E. McGraw, Alain C. Borczuk, Ashish Saxena, Jeffrey L. Port, Brendon M. Stiles, Benjamin E. Lee, Nicholas J. Sanfilippo, Ronald J. Scheff, Bradley B. Pua, James F. Gruden, Paul J. Christos, Cathy Spinelli, Joyce Gakuria, Manik Uppal, Bhavneet Binder, Olivier Elemento, Karla Ballman, Silvia C. Formenti
Summary: The combination of neoadjuvant durvalumab and stereotactic body radiotherapy in early-stage NSCLC patients shows a high major pathological response rate and is well tolerated, suggesting its potential in treatment, although it comes with certain adverse events.
Article
Oncology
Craig S. Schneider, Robert A. Oster, Aparna Hegde, Michael C. Dobelbower, John M. Stahl, Adam J. Kole
Summary: A considerable proportion of inoperable patients with large, node-negative NSCLC are not treated according to NCCN Guidelines and receive concurrent chemoradiotherapy. Younger patients with larger tumors receiving treatment at nonacademic medical centers were more likely to receive nonadherent therapy, but adherence to NCCN Guidelines was not associated with differences in overall survival.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2022)
Article
Multidisciplinary Sciences
Arta M. Monjazeb, Megan E. Daly, Guillaume Luxardi, Emanual Maverakis, Alexander A. Merleev, Alina I. Marusina, Alexander Borowsky, Amin Mirhadi, Stephen L. Shiao, Laurel Beckett, Shuai Chen, David Eastham, Tianhong Li, Logan V. Vick, Heather M. Mcgee, Frances Lara, Leslie Garcia, Leigh Anne Morris, Robert J. Canter, Jonathan W. Riess, Kurt A. Schalper, William J. Murphy, Karen Kelly
Summary: Stereotactic ablative radiotherapy (SABR) is a standard-of-care for medically-inoperable-early-stage non-small cell lung cancer (NSCLC). A phase I study tested the addition of atezolizumab to SABR in high risk, medically inoperable, early-stage NSCLC, and found that it was well tolerated and showed efficacy signals.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Nima Aghdam, Jonathan W. Lischalk, Monica Pernia Marin, Clare Hall, Timothy O'Connor, Lloyd Campbell, Simeng Suy, Sean P. Collins, Marc Margolis, Rebecca Krochmal, Eric Anderson, Brian T. Collins
Summary: SBRT is a standard treatment for medically inoperable early stage non-small cell lung cancer. Central tumor location and lobar gross endobronchial disease (LGED) are identified as risk factors for severe treatment-related toxicity and poor overall survival. Further research in larger datasets is needed to validate these findings.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Alexander Piening, Anand Swaminath, John Dombrowski, Ryan M. Teague, Noor Al-Hammadi, Jeevin Shahi
Summary: The study found that advanced hepatocellular carcinoma patients who received ST+SBRT had better overall survival compared to those who received ST alone. This suggests that combination therapy plays a positive role in improving survival in patients with advanced HCC.
FRONTIERS IN ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Toshiki Ikawa, Takahiro Tabuchi, Koji Konishi, Masahiro Morimoto, Takero Hirata, Naoyuki Kanayama, Kentaro Wada, Masayasu Toratani, Sumiyo Okawa, Kazuhiko Ogawa, Teruki Teshima
Summary: In a retrospective study of 200 patients with early-stage non-small-cell lung cancer, consecutive stereotactic body radiotherapy was found to provide better local control and overall survival compared to non-consecutive treatment. The prolonged overall treatment time negatively impacted outcomes in patients undergoing stereotactic body radiotherapy.
Article
Oncology
Rishabh K. Simhal, Tamir N. Sholklapper, Anish K. Simhal, Alan L. Zwart, Malika T. Danner, Deepak Kumar, Nima Aghdam, Simeng Suy, Ryan A. Hankins, Keith J. Kowalczyk, Sean P. Collins
Summary: This study investigated the role of FACIT-F as a baseline predictor for overall survival in patients undergoing SBRT for localized PCa. Results showed that FACIT-F scores were significantly associated with OS, with higher scores indicating less fatigue and better overall survival.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Megan E. Daly
Summary: Stereotactic ablative radiotherapy (SABR) is the standard treatment for medically inoperable, early-stage non-small-cell lung cancer. However, regional and distant failures remain a challenge, especially in larger and more biologically aggressive tumors. Use of cytotoxic chemotherapy is limited in this patient population, prompting the investigation of alternative systemic therapy options with fewer side effects, such as immune checkpoint inhibitors.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Henan Zhang, Jacob J. Orme, Feven Abraha, B. J. Stish, Val J. Lowe, Fabrice Lucien, Erik J. Tryggestad, Michael S. Bold, Lance C. Pagliaro, C. Richard Choo, Debra H. Brinkmann, Matthew J. Iott, Brian J. Davis, J. Fernando Quevedo, William S. Harmsen, Brian A. Costello, Geoffrey B. Johnson, Mark A. Nathan, Kenneth R. Olivier, Thomas M. Pisansky, Eugene D. Kwon, Haidong Dong, Sean S. Park
Summary: The study showed that high levels of tumor-reactive T cells and effector memory T cells were associated with better outcomes in oligometastatic CRPC patients treated with SABR. This supports the incorporation of immune-based markers in the design of future randomized trials in this patient population.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Robert Olson, Will Jiang, Mitchell Liu, Alanah Bergman, Devin Schellenberg, Benjamin Mou, Abraham Alexander, Hannah Carolan, Fred Hsu, Stacy Miller, Siavash Atrchian, Elisa Chan, Clement Ho, Islam Mohamed, Angela Lin, Tanya Berrang, Andrew Bang, Nick Chng, Quinn Matthews, Sarah Baker, Vicky Huang, Ante Mestrovic, Derek Hyde, Chad Lund, Howard Pai, Boris Valev, Shilo Lefresene, Scott Tyldesley
Summary: This study confirms that the incidence of high-grade toxic effects in the large cohort of patients receiving SABR for oligometastases is less than 5%. The lower rates of toxic effects compared to previous studies may support further enrollment in randomized phase 3 clinical trials.
Article
Oncology
Rogier Baak, Francois E. J. A. Willemssen, Yvette van Norden, Ferry A. L. M. Eskens, Maaike T. W. Milder, Ben J. M. Heijmen, Bas Groot Koerkamp, Dave Sprengers, Lydi M. J. W. van Driel, Heinz-Josef Klumpen, Wilhelm den Toom, Merel S. Koedijk, Jan N. M. IJzermans, Alejandra Mendez Romero
Summary: This study examined the feasibility and safety of adding SBRT treatment in patients with unresectable perihilar cholangiocarcinoma, showing promising results in terms of local control and overall survival. However, further evaluation in a larger patient population is recommended due to the small sample size in this study.
Article
Oncology
Laura Cella, Serena Monti, Maria Thor, Andreas Rimner, Joseph O. Deasy, Giuseppe Palma
Summary: Radiation-induced dyspnea is a common side-effect of thoracic radiation therapy, and this study aimed to predict its occurrence within six months after stereotactic body radiation therapy for non-small cell lung cancer. Risk factors identified included pre-treatment chronic obstructive pulmonary disease, higher lung and heart radiation doses. A predictive model using patient comorbidity, heart volume, and lung radiation doses showed promising performance for dyspnea prediction.
Article
Medicine, General & Internal
Annaig Bertho, Morgane Dos Santos, Sarah Braga-Cohen, Valerie Buard, Vincent Paget, Olivier Guipaud, Georges Tarlet, Fabien Milliat, Agnes Francois
Summary: By utilizing three-fraction schedules delivered over a period of 1 week with doses per fraction of 20, 28, 40, and 50 Gy, only 3 x 40 Gy or 3 x 50 Gy generated focal lung fibrosis after 6 months. The study suggests that a fractionation schedule using an arc-therapy-delivered three fractions/1 week regimen with 3 x 3 mm beam requires 40 Gy per fraction for lung fibrosis to develop within 6 months.
FRONTIERS IN MEDICINE
(2021)
Article
Surgery
Maxwell T. Trudeau, Fabio Casciani, Brett L. Ecker, Laura Maggino, Thomas F. Seykora, Priya Puri, Matthew T. McMillan, Benjamin Miller, Wande B. Pratt, Horacio J. Asbun, Chad G. Ball, Claudio Bassi, Stephen W. Behrman, Adam C. Berger, Mark P. Bloomston, Mark P. Callery, Carlos Fernandez-del Castillo, John D. Christein, Mary E. Dillhoff, Euan J. Dickson, Elijah Dixon, William E. Fisher, Michael G. House, Steven J. Hughes, Tara S. Kent, Giuseppe Malleo, Ronald R. Salem, Christopher L. Wolfgang, Amer H. Zureikat, Charles M. Vollmer
Summary: This study aims to present different patient presentations of pancreatic fistula risk and define the effectiveness of mitigation strategies in the most prevalent and vulnerable scenarios for surgeons. Through analysis of data from multiple international institutions, specific scenarios and optimal mitigation approaches associated with CR-POPF occurrence were identified.
Review
Health Care Sciences & Services
J. Isabelle Choi, Jana Fox, Richard Bakst, Shaakir Hasan, Robert H. Press, Arpit M. Chhabra, Brian Yeh, Charles B. Simone, Oren Cahlon
Summary: Partial breast irradiation (PBI) delivered with proton therapy offers a shorter treatment duration and reduced toxicities, targeting less non-target breast tissue and limiting unnecessary radiation dose to thoracic organs. Proton therapy is a precision radiotherapy technology that further limits normal tissue exposure to improve quality of life for early stage breast cancer patients.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Oncology
Minglei Kang, Shouyi Wei, J. Isabelle Choi, Charles B. Simone, Haibo Lin
Summary: This study focuses on quantifying the dose rate of organs-at-risk and targets based on three proposed proton PBS dose rate metrics, showing significant impact of differences in dose rate metrics on the assessment of organ-at-risk dose rate, posing challenges to the clinical implementation of FLASH. Additional investigations are needed to explore the correlation between FLASH efficacy and the dose rate metrics in proton PBS therapy.
Article
Oncology
Shouyi Wei, Haibo Lin, J. Isabelle Choi, Charles B. Simone, Minglei Kang
Summary: This study compares the performance of single-energy Bragg peak proton beams with transmission proton beams in lung tumor treatment planning, finding that Bragg peak plans achieve superior dosimetry performances in OARs while maintaining comparable dose rate performances. Beam angle optimization further improves OAR dosimetry parameters without compromising the 3D FLASH dose rate coverage.
Article
Oncology
Weiwei Wang, Matthew T. McMillan, Xinyi Zhao, Zhuwen Wang, Long Jiang, David Karnak, Fatima Lima, Joshua D. Parsels, Leslie A. Parsels, Theodore S. Lawrence, Timothy L. Frankel, Meredith A. Morgan, Michael D. Green, Qiang Zhang
Summary: Combining DNA-PK inhibitor with radiation enhances antitumor immunity and increases sensitivity to anti-PD-L1 in pancreatic cancer models.
MOLECULAR CANCER RESEARCH
(2022)
Review
Oncology
Jana M. Kobeissi, Charles B. Simone, Haibo Lin, Lara Hilal, Carla Hajj
Summary: Radiation therapy plays a central role in the management of pancreatic cancer, and proton therapy is an emerging treatment modality. Proton irradiation remains a challenge in radiation therapy, but no significant differences in oncologic outcomes and toxicity rates have been shown compared to photon radiation treatment.
Review
Oncology
Jana M. Kobeissi, Charles B. Simone, Lara Hilal, Abraham J. Wu, Haibo Lin, Christopher H. Crane, Carla Hajj
Summary: Radiation treatment is crucial in managing luminal gastrointestinal cancers, particularly esophageal and anorectal cancers. Proton therapy is gaining interest for its ability to decrease dose to nearby organs at risk. In esophageal cancer, protons have shown superior dosimetric characteristics in sparing organs at risk, but clinical significance is conflicting. However, evidence suggests that protons offer similar or improved oncologic outcomes with reduced toxicity compared to photons. In anorectal cancers, proton therapy has shown improved organ sparing, but clinical data is limited and toxicity benefits have not been clinically proven.
Review
Oncology
Jana M. Kobeissi, Lara Hilal, Charles B. Simone, Haibo Lin, Christopher H. Crane, Carla Hajj
Summary: This review provides a concise and comprehensive summary on the use of proton therapy in the management of hepatocellular carcinoma (HCC). Proton radiation therapy plays a central role in the treatment of HCC, and evidence suggests it may be superior to photons in terms of survival and toxicity outcomes.
Article
Oncology
Beatriz E. Amendola, Anand Mahadevan, Jesus Manuel Blanco Suarez, Robert J. Griffin, Xiaodong Wu, Naipy C. Perez, Daniel S. Hippe, Charles B. Simone Ii, Majid Mohiuddin, Mohammed Mohiuddin, James W. Snider, Hualin Zhang, Quynh-Thu Le, Nina A. Mayr
Summary: SFRT shows promising potential as a new treatment modality for challenging tumors. However, the development of clinical trials is hindered by the variability in SFRT methods and the unfamiliarity with heterogeneous dosing, requiring a broad consensus.
Article
Medicine, General & Internal
Rulon Mayer, Baris Turkbey, Peter L. Choyke, Charles B. Simone
Summary: This study predicts the risk of clinically significant prostate cancer (CsPCa) and correlates it with the ISUP grade using processed SCR derived from SRBP-MRI. The results show a high correlation between SCR values and ISUP grade and CsPCa/CiPCa, indicating the potential of SRBP-MRI in non-invasive management of prostate cancer.
Article
Oncology
Michael Pennock, Shouyi Wei, Chingyun Cheng, Haibo Lin, Shaakir Hasan, Arpit M. Chhabra, J. Isabelle Choi, Richard L. Bakst, Rafi Kabarriti, Charles B. Simone II, Nancy Y. Y. Lee, Minglei Kang, Robert H. Press
Summary: Bragg peak proton FLASH is a novel radiotherapy technique that combines ultra-high dose rates and conformal organ sparing for cancer treatment. By modifying the planning software and treatment delivery, Bragg peak FLASH can improve organ sparing and target coverage compared to conventional proton therapy. This study demonstrates the potential benefits of Bragg peak proton FLASH in head and neck reirradiation.
Article
Oncology
Grant Lattery, Tyler Kaulfers, Chingyun Cheng, Xingyi Zhao, Balaji Selvaraj, Haibo Lin, Charles B. Simone II, J. Isabelle Choi, Jenghwa Chang, Minglei Kang
Summary: This study focused on developing ultra-high dose rate intensity-modulated proton therapy (IMPT) for hypofractionated treatment of early-stage breast cancer. The results showed that the Bragg peak FLASH-RT technique achieved comparable plan quality to conventional IMPT, demonstrating the feasibility of early-stage breast cancer clinical applications.
Article
Oncology
Pingfang Tsai, Yu-Lun Tseng, Brian Shen, Christopher Ackerman, Huifang A. Zhai, Francis Yu, Charles B. Simone II, J. Isabelle Choi, Nancy Y. Lee, Rafi Kabarriti, Stanislav Lazarev, Casey L. Johnson, Jiayi Liu, Chin-Cheng Chen, Haibo Lin
Summary: This study evaluates the potential of cone-beam computed tomography (CBCT)-based synthetic CT (sCT) as an alternative to verification CT (vCT) in proton therapy for enhanced treatment monitoring and early adaptation. The study found that sCT agreed with vCT in regions of homogeneous tissues, but discrepancies were observed in the thorax and abdomen. The study also observed outliers in sCT plans when there was an anatomy change or in low-density regions. The target coverage variance in most sCT cases compared to vCT was less than 5%. The study concludes that the use of sCT allows for precise treatment and prompt early adaptation in proton therapy, but quality assurance of sCT is crucial in the early stages of clinical implementation.
Article
Medicine, General & Internal
Rulon Mayer, Baris Turkbey, Peter L. Choyke, Charles B. Simone
Summary: This study aims to assess tumor aggressiveness through analysis of bi-parametric MRI images using methods like signal to clutter ratio. The results show that the processed tumor eccentricity and volume computations from spatially registered BP-MRIs have a significant correlation with the ISUP grade.
Article
Surgery
Maxwell T. Trudeau, Laura Maggino, Bofeng Chen, Matthew T. McMillan, Major K. Lee, Robert Roses, Ronald DeMatteo, Jeffrey A. Drebin, Charles M. Vollmer
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
(2020)